[topsearch__bar__shortcode]

Motus GI Holdings Inc. (MOTS) stock Rallies Premarket Following a Series of Stock Option Awards

[breadcrumb_custom]

Related Topics

Facebook
Twitter
LinkedIn
WhatsApp

On February 11, 2022, Motus GI Holdings Inc. (MOTS) filed a series of Forms with the Securities Exchange Commission regarding certain option awards. Consequently, the stock rallied in the premarket on Monday.

In the previous trading session, the stock remained in the red with a loss of 6.33% at $0.4250. Following the SEC filings of the company, MOTS rebounded in the premarket to gain a huge 57.65% at the last check. Hence, the stock was trading at $0.67 in the premarket, at the time of writing on Monday.

The medical technology company, Motus GI Holdings Inc. is working on improving endoscopy outcomes and experiences. Currently, the company has a market capitalization of $20.52 million with 48.28 million shares outstanding. In the past five days, MOTS had added 8.95% while it has declined by 8.99% year to date. Furthermore, the stock subtracted a value of 75.43% last year.

Recent Option Awards

On Friday, the company registered as many as eight SEC filings regarding certain option awards. The option awards were granted to various members of the company including Morgan Timothy P., (Director & CEO), Mark Pomeranz (president, COO & director), and David P. Hochman (Chairman). MOTS’ independent directors, Nelson Sonja, Sherman Darren, Shervin Joe Korangy, and Gary J. Pruden were also granted option awards. Additionally, an officer of the company, Taylor Andrew Lawrence was also on the list of the names.

These stock options were granted to the mentioned personnel of the company in accordance with its 2016 Equity Incentive Plan. Further details of the option awards are present on the company’s SEC filings page.

MOTS Innovation Day

On January 25, the company hosted an Innovation Day focusing on its Pure-Vu EVS System. The innovation day highlighted various aspects of the system including its commercial expansion and future product innovation. Moreover, the clinical initiatives for supporting reimbursement and market growth were also highlighted during the event.

Pure-Vu EVS Systems, the third-gen Pure-Vu platform is designed for ease of use advancement. It offers enhanced physician navigation, control, on-demand bedside loading, expanded cleansing all with a much smaller workstation footprint. Presently, the system is under 510(k) review by the FDA.

MOTS’ Financial Highlights

In the third quarter of 2021, the company had a net loss of $4.8 million on revenue of $141,000. This compares to a net loss of $3.9 million on revenue of $33,000 in Q3 of 2020. Therefore, the net loss per basic and diluted share was $0.10 and $0.13 in the third quarter of 2021 and 2020, respectively.

 

Leave a Comment

Your email address will not be published. Required fields are marked *

Latest Posts